HAE
Haemonetics Corporation
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
108.80
▲ 0.58 (0.54%)
MARKET · —
Price
Open
108.00
Prev close
108.22
Day high
109.57
Day low
107.01
Volume
443.49K
Market cap
$4.95B
P/E (TTM)
52.56
52W range
47.32 – 109.57
Trailing performance
Returnvs SPY
1W
+19.82%
+21.2%
1M
+40.57%
+36.8%
3M
+75.65%
+72.6%
6M
+77.81%
+66.7%
YTD
+35.75%
+23.5%
1Y
+99.82%
+79.8%
3Y
+18.91%
-55.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$4.95B
Enterprise value$5.90B
Revenue (TTM)$1.35B
Gross profit$802.16M
EBITDA$358.79M
Net income$96.29M
EPS (TTM)$2.07
Free cash flow$312.84M
Total cash$224.52M
Total debt$1.17B
Book value / share$18.41
Shares outstanding45.50M
Float44.89M
Short % of float7.51%
Dividend yield—
Beta (5Y)0.52
Valuation & profitability ratios
Trailing P/E52.56
Forward P/E18.96
PEG ratio1.72
Price / sales—
Price / book5.91
EV / revenue4.36
EV / EBITDA16.44
Gross margin59.33%
Operating margin17.93%
Profit margin7.12%
Return on equity11.20%
Return on assets6.60%
Debt / equity140.27
Current ratio3.08
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Total revenue | $1.33B | $1.36B | $1.31B | $1.17B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $97.31M | $167.68M | $117.56M | $115.40M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | $97.31M | $167.68M | $117.56M | $115.40M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.08 | 1.14 | +5.9% |
| Mar 2026 | 1.27 | 1.29 | +1.4% |
| Dec 2025 | 1.25 | 1.31 | +4.8% |
| Sep 2025 | 1.11 | 1.27 | +14.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.29 | 11 | $345.03M | +5.4% |
| Next quarter | 1.35 | 11 | $356.65M | +5.2% |
| Current year | 5.30 | 11 | $1.41B | +6.1% |
| Next year | 5.74 | 11 | $1.49B | +5.3% |
Analyst targets & ownership
Mean target$104.10
High target$120.00
Low target$86.00
Implied upside-4.32%
Analyst count10
ConsensusBUY
Strong buy / Buy4 / 4
Hold3
Sell / Strong sell0 / 0
Held by insiders1.26%
Held by institutions112.60%
Institutions holding464
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
574.63K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 24, 26 | KROLL MARK W Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | ABERNATHY ROBERT E Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | COYLE MICHAEL J Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | ZANE ELLEN M Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | MADAUS MARTIN D PH.D. Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | POMEROY CLAIRE Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | BRYANT DIANE M Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | JOHNSON LLOYD EMERSON Director |
STOCK | 2.54K | $0 | Direct |
| May 15, 26 | DARECCA JAMES Chief Financial Officer |
STOCK | 29.31K | $0 | Direct |
| May 15, 26 | MILLER LAURIE A Officer |
STOCK | 13.32K | $0 | Direct |
| May 15, 26 | GALVIN ROY Officer |
STOCK | 27.54K | $0 | Direct |
| May 15, 26 | MAUNSELL FARRIS MARYANNE Officer |
STOCK | 2.22K | $0 | Direct |
| May 15, 26 | SIMON CHRISTOPHER Chief Executive Officer |
STOCK | 78.34K | $0 | Direct |
| May 15, 26 | BASIL MICHELLE L General Counsel |
STOCK | 28.42K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABERNATHY ROBERT E |
Director | 27.52K | Stock Award(Grant) |
BASIL MICHELLE L |
General Counsel | 68.83K | Stock Award(Grant) |
DARECCA JAMES |
Chief Financial Officer | 54.44K | Stock Award(Grant) |
DOCKENDORFF CHARLES J |
Director | 25.04K | Stock Award(Grant) |
GALVIN ROY |
Officer | 39.88K | Stock Award(Grant) |
KROLL MARK W |
Director | 27.30K | Stock Award(Grant) |
MILLER LAURIE A |
Officer | 41.30K | Stock Award(Grant) |
POMEROY CLAIRE |
Director | 19.41K | Stock Award(Grant) |
SIMON CHRISTOPHER |
Chief Executive Officer | 444.70K | Stock Award(Grant) |
ZANE ELLEN M |
Director | 21.91K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
96.67
+12.55% from price
SMA 20
90.68
+19.99% from price
SMA 50
81.85
+32.92% from price
SMA 100
71.52
+52.12% from price
SMA 200
70.83
+53.61% from price
EMA 12
97.42
+11.68% from price
EMA 26
90.22
+20.59% from price
EMA 50
83.49
+30.31% from price
RSI (14)
84.6
Overbought
MACD (12,26,9)
7.20
Hist 2.11
ATR (14)
4.13
3.79% of price
Realised vol 30D
49.6%
Annualised
Bollinger upper
108.45
20, 2σ
Bollinger lower
72.91
20, 2σ
50 / 200 cross
Golden
81.85 vs 70.83
Trend bias
Above 200
+53.61%
Risk profile
Beta vs SPY
0.14
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
49.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-40.1%
Peak to trough
Max drawdown 5Y
-51.0%
Peak to trough
ATR 14
4.13
3.79% of price
Beta (reported)
0.52
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.84
Call-heavy session
Put / call open interest
0.26
Positioning, not flow
Max pain
70.00
-35.7% from spot
ATM implied vol
42.1%
Nearest strike to spot
Skew (10% OTM)
+5.3%
Puts bid over calls
Call volume
50
Contracts, this expiry
Put volume
42
Contracts, this expiry
Heaviest call OI
80.00
220 contracts
Heaviest put OI
105.00
75 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
StockStory · 20h ago
1 Russell 2000 Stock with Competitive Advantages and 2 We Turn Down
StockStory · 2d ago
Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating
MT Newswires · 3d ago
Sector Update: Healthcare Stocks Climb Late Afternoon
MT Newswires · 4d ago
Sector Update: Healthcare
MT Newswires · 4d ago
Haemonetics Shares Rise After Signing Supply Agreement With CSL Plasma
MT Newswires · 4d ago
1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid
StockStory · 5d ago
Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance
Simply Wall St. · 7d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.